new transurethral therapy in patients with moderate to severe symptoms.
INTRODUCTION AND OBJECTIVES:
Benign prostatic hyperplasia (BPH) with associated lower urinary tract symptoms (LUTS) has a significant impact on quality of life. Multi-institutional projects have demonstrated Prostatic urethral lift (PUL) as a minimally invasive procedure with strong 5-year durability, minimal side effect profile, and no associated erectile or ejaculatory dysfunction. Long term single series data are needed. This studies purpose was to report on, to our knowledge, the largest single surgeon series of PUL.
METHODS: We completed a retrospective chart review of men who underwent PUL in the office from June 2016 to May 2018. PUL, also known as Urolift (NeoTract, Pleasanton, CA, USA), was performed in the office by a single surgeon. International prostatic symptom score (IPSS), quality of life (QOL), and post void residuals (PVR) were recorded at baseline and at subsequent office visits. A paired-samples T-test was used to compare pre and post treatment values.
RESULTS: We identified 156 men who had undergone a PUL. Descriptive statistics demonstrated an average age of 69 AE 11.9, prostate volume of 53.9 AE 29.1, number of implants used 5.5 AE 0.9, and post-operative catheter duration of 1.6 AE 1.8 days. When comparing IPSS, QOL, and PVR 151, 142, and 116 paired samples were available and the mean follow up period was 7.6 AE 5.8 [Range 0.5-24] months. IPSS values improved significantly 65% from 18.9 AE 7.4 to 6.7 AE 5.0 (-12.2 AE 7.7 p<0.05). QOL improved significantly 59% from 4.1 AE 1.3 to 1.7 AE 1.3 (-2.4 AE 1.7 p<0.05). Similarly, PVR decreased significantly 58% from 153.1 AE 232.8 to 64.2 AE 125.4 (-88.9 AE 150.6 p<0.05).
CONCLUSIONS: To our knowledge, this is the largest single surgeon series reported on PUL. Our data demonstrated statistically significant improvement in IPSS 65%, QOL 59%, and PVR 58% at an average of 7.6 months. As our data set matures we hope to externally validate prior studies as well as report on patient group previous excluded from PUL, including patients in urinary retention, prostate volumes <30 or >80 grams, and having prior prostate interventions. ) . We present the results of a one-arm, multi-center, international prospective study to define the efficacy of second generation of MediTate i-TIND in subjects with BPH.
METHODS: The i-TIND is composed of three nitinol elongated struts and an anchoring leaflet. It is preloaded by crimping it into the delivery system. When positioned, the struts of expand and determine a radial force with ischemic necrosis and incision of bladder neck and prostatic urethra. The inclusion criteria were: IPSS > 10; peak urinary flow (Qmax) < 12 mL/sec and prostate volume < 75 cc. All patients stopped alpha-blockers and 5alpha-reductase inhibitors before the implantation. The procedure was performed using a rigid 17F cystoscope, under light sedation. 5 days after the implantation the device was removed, without anesthesia. We evaluated demographic, perioperative, functional results and quality of life (QoL) questionnaire. We reported the results at 3, 6 and 12 months.
RESULTS: The mean (SD) patient age was 65 (8.9) years, the mean (SD) prostate volume was 40.5 (12.25) mL, mean (SD) Qmax was 7.3 (AE2.6 ml/sec), mean (SD) IPSS score was 22.5 (AE5.6) and median (SD) IPSS QoL was 4 (2:5). No intraoperative complications were recorded. The devices were retrieved 5.9AE1.1 days following implantation. No >grade 2 complications were recorded.
Mean Qmax at 1 month follow-up stood at 11.2AE5.7 mL/sec and continued to improve thereafter, reaching 14.9AE8.1 mL/sec at the 12 month follow-up visit (þ 100%). IPSS urinary symptom scores was 11.7AE 8.0 after 1 month and further improved to 8.8AE6.4 at the 12 month follow-up (-60%). Mean QoL IPSS score drop reached 1.6AE1.3 by the end of the study. During the 12 month period, 2 patients (2.4%) required medications for BPH, 2 patients (2.4%) required TURP. As compared to baseline, none of the 61 sexually active patients who completed the 1 year follow up period reported sexual or ejaculatory dysfunction.
CONCLUSIONS: More studies are necessary to define the durability of the results but second generation i-TIND implantation is a safe and effective minimally-invasive technique for the treatment of BPH related symptoms until one year follow up.
